Table 4

CTLA-4 blockade: Ongoing and recruiting phase III trials (98)

ClinicalTrials.gov IdentifierTreatment Arm(s)Patient PopulationPrimary Outcome MeasureStatusSponsor
NCT00324155Ipilimumab/Dacarbazine vs. Placebo/DacarbazineUntreated unresectable Stage III or Stage IV melanomaOSOngoingBristol-Myers Squibb
NCT00636168Ipilimumab vs. PlaceboCompletely resected high-risk Stage III melanomaRFSOngoingBristol-Myers Squibb
NCT01274338Ipilimumab at high-dose vs. Ipilimumab at low-dose vs. Recombinant interferon alfa-2bHigh-risk Stage III or Stage IV melanoma that has been removed by surgeryRFS, OSRecruitingEastern Cooperative Oncology Group
NCT01515189Ipilimumab 3 mg/kg vs. Ipilimumab 10 mg/kgUnresectable or metastatic melanomaOSOngoingBristol-Myers Squibb
NCT00861614Ipilimumab vs. Placebo, each following a single dose of RTAdvanced CRPC post-docetaxelOSRecruitingBristol-Myers Squibb
NCT01057810Ipilimumab vs. PlaceboAsymptomatic or minimally symptomatic chemotherapy-naïve metastatic CRPCOSRecruitingBristol-Myers Squibb
NCT01285609Ipilimumab/Paclitaxel/Carboplatin vs. Placebo/Paclitaxel/CarboplatinSquamous NSCLCOSRecruitingBristol-Myers Squibb
NCT01450761Ipilimumab/Etoposide/Cisplatin or Carboplatin vs. Placebo/Etoposide/Cisplatin or CarboplatinExtensive-stage SCLCOSRecruitingBristol-Myers Squibb